Odyssey Therapeutics, Inc. - Common Stock (ODTX)
19.36
-0.18 (-0.92%)
NASDAQ · Last Trade: Nov 2nd, 1:46 PM EST
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readoutsmarketbeat.com
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor webcast. The company said the complete induction dataset, biomarker findings an
Via MarketBeat · October 25, 2026